
Location: London, UK (Laboratory based- role)
Reporting to: Principal Scientist, Global Technical Development
Job Summary
Reporting to the Principal Scientist, Global Technical Development, the Associate Scientist will contribute towards laboratory-based activities supporting lentiviral vector (LVV) process development. Under supervision, the Associate Scientist will execute upstream and downstream process studies, vector analytics, and generation of high-quality technical documentation, while collaborating with cross-functional teams to support development, technology transfer, and CMC deliverables across the programmes.
Key Elements and Responsibilities
Core Activities
Lab maintenance
Broader Technical Development & CMC Exposure
Required Knowledge
· Experience in biotechnology/biological sciences or equivalent. Experience in cell and gene therapy is highly desirable.
· Understanding of vector manufacturing process operations including cell culture (adherent and/or suspension platforms), filtration, chromatography and tangential flow filtration operations. Practical experience in at least 2 of the above process steps is required.
· Understanding of analytical methods associated with gene therapy vectors and /or autologous gene-modified cellular therapies. Practical experience in vector analytics is highly desirable.
· Confident in performing various laboratory techniques, especially in aseptic culturing, with the ability to quickly learn and develop new practical skills.
Skills and Abilities
· Excellent interpersonal skills
· Outstanding organizational skills
· Excellent written and oral communication skills
· Creative problem solver
· Ability to operate in a fast-paced, multi-disciplinary industrial environment
Education
· A minimum of BSc or equivalent in bioprocessing, biological sciences, gene therapy or related subject.
Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment.
Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.
For more information, please visit https://www.orchard-tx.com/.
Take the next step in your career journey